A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
Summary
- Eligibility
- for people ages 50-80 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Eveline Stock
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Eveline Stock
Dr. Eveline Oestreicher Stock is a cardiologist specializing in general cardiology and cholesterol metabolism disorders. Her special interests include preventive cardiology, mechanisms of coronary artery disease, heart disease risk assessment, and heart disease women and in the young.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- ID
- NCT05646381
- Phase
- Phase 2 Aortic Stenosis Research Study
- Study Type
- Interventional
- Participants
- Expecting 502 study participants
- Last Updated